Investigational drug · Phase 3
MC0518
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Steroid-refractory Acute Graft-versus-host Disease.
Phase 3Last checked: Nov 19, 2026Latest source record: Apr 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "MC0518"
First trial start
2021
Aug 16, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MC0518", any sponsor or status.
Conditions studied
As listed on its trial records.
- Steroid-refractory Acute Graft-versus-host Disease
Largest trials
Live from ClinicalTrials.gov: studies naming "MC0518" as an intervention, largest first.
- Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available TherapyPivotal-lookingRecruiting
medac GmbHIndustry
NCT04629833 · 210 participants (planned) · Start Aug 16, 2021 · Primary completion Aug 2027
Drug: MC0518; BAT · For: Steroid-refractory Acute Graft-versus-host Disease
Sites: Amiens, France; Besançon, France; Grenoble, France · 42 sites in all
- Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants With Steroid-Refractory Acute Graft Versus Host DiseaseActive, not recruiting
medac GmbHIndustry
NCT06075706 · 49 participants · Start Nov 13, 2023 · Primary completion Feb 11, 2026
Drug: MC0518; BAT · For: Steroid-refractory Acute Graft-versus-host Disease
Sites: Bordeaux, France; La Tronche, France; Lille, France · 36 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Clinical Development Programme of the Innovative Mesenchymal Stromal Cell Product MSC-FFM/MC0518 for Steroid-Refractory Acute Graft-Versus-Host Disease: Design of 2 Randomised Controlled Trials in Adult and Paediatric Patients.
Zeiser R, Bönig H, Osswald E, et al. · Transfus Med Hemother 2026
- Non-clinical assessment of safety, biodistribution and tumorigenicity of human mesenchymal stromal cells.
Thäte C, Woischwill C, Brandenburg G, et al. · Toxicol Rep 2021
Also in development for Steroid-refractory Acute Graft-versus-host Disease
- VUM02Phase 21 trial
Wuhan Optics Valley Vcanbiopharma Co., Ltd. · Steroid-refractory Acute Graft-versus-host Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.